Cargando…
Evaluation of the potential herb-drug interaction between Bojungikki-tang and PD-L1 immunotherapy in a syngeneic mouse model
Atezolizumab (a PD-L1 inhibitor) has shown remarkable efficacy and tolerability in various cancer types. Despite its efficacy and safety, atezolizumab monotherapy has limitations, such as acquired resistance and adverse events. Bojungikki-tang (BJIKT) is an herbal decoction widely prescribed in Asia...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232755/ https://www.ncbi.nlm.nih.gov/pubmed/37274110 http://dx.doi.org/10.3389/fphar.2023.1181263 |
_version_ | 1785052057714032640 |
---|---|
author | Yang, Sung-Yoon Yi, Jin-Mu Chun, Jaemoo Park, Seongwon Bui, Tham Thi Yun, Hwi-Yeol Chae, Jung-Woo Jeong, Mi-Kyung |
author_facet | Yang, Sung-Yoon Yi, Jin-Mu Chun, Jaemoo Park, Seongwon Bui, Tham Thi Yun, Hwi-Yeol Chae, Jung-Woo Jeong, Mi-Kyung |
author_sort | Yang, Sung-Yoon |
collection | PubMed |
description | Atezolizumab (a PD-L1 inhibitor) has shown remarkable efficacy and tolerability in various cancer types. Despite its efficacy and safety, atezolizumab monotherapy has limitations, such as acquired resistance and adverse events. Bojungikki-tang (BJIKT) is an herbal decoction widely prescribed in Asian countries and used to treat cancer-related symptoms including fatigue, appetite loss, gastrointestinal disorders, and other side effects from cancer therapy. Due to its immunomodulatory effects, Bojungikki-tang has been investigated as a combined treatment with anticancer agents. We evaluated the potential drug-drug interaction (DDI) between Bojungikki-tang and the anti-PD-L1 antibody based on the Food and Drug Administration (FDA) guidelines. In the study, we conducted an in vivo drug-drug interaction study using a syngeneic mouse model of CMT-167 in C57BL/6. We then determined the antibody concentrations to evaluate the pharmacokinetic (PK) drug-drug interaction and measured variable biomarkers related to therapeutic efficacy and immune response. The pharmacodynamic (PD) drug-drug interaction study investigated changes in response between anti-PD-L1 antibody monotherapy and combination therapy. Using the pharmacokinetic and pharmacodynamic data, we conducted a statistical analysis to assess drug-drug interaction potential. In the presence of Bojungikki-tang, the pharmacokinetic characteristics of the anti-PD-L1 antibody were not changed. This study suggested that combination treatment with Bojungikki-tang and atezolizumab is a safe treatment option for non-small cell lung cancer. Clinical studies are warranted to confirm this finding. |
format | Online Article Text |
id | pubmed-10232755 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102327552023-06-02 Evaluation of the potential herb-drug interaction between Bojungikki-tang and PD-L1 immunotherapy in a syngeneic mouse model Yang, Sung-Yoon Yi, Jin-Mu Chun, Jaemoo Park, Seongwon Bui, Tham Thi Yun, Hwi-Yeol Chae, Jung-Woo Jeong, Mi-Kyung Front Pharmacol Pharmacology Atezolizumab (a PD-L1 inhibitor) has shown remarkable efficacy and tolerability in various cancer types. Despite its efficacy and safety, atezolizumab monotherapy has limitations, such as acquired resistance and adverse events. Bojungikki-tang (BJIKT) is an herbal decoction widely prescribed in Asian countries and used to treat cancer-related symptoms including fatigue, appetite loss, gastrointestinal disorders, and other side effects from cancer therapy. Due to its immunomodulatory effects, Bojungikki-tang has been investigated as a combined treatment with anticancer agents. We evaluated the potential drug-drug interaction (DDI) between Bojungikki-tang and the anti-PD-L1 antibody based on the Food and Drug Administration (FDA) guidelines. In the study, we conducted an in vivo drug-drug interaction study using a syngeneic mouse model of CMT-167 in C57BL/6. We then determined the antibody concentrations to evaluate the pharmacokinetic (PK) drug-drug interaction and measured variable biomarkers related to therapeutic efficacy and immune response. The pharmacodynamic (PD) drug-drug interaction study investigated changes in response between anti-PD-L1 antibody monotherapy and combination therapy. Using the pharmacokinetic and pharmacodynamic data, we conducted a statistical analysis to assess drug-drug interaction potential. In the presence of Bojungikki-tang, the pharmacokinetic characteristics of the anti-PD-L1 antibody were not changed. This study suggested that combination treatment with Bojungikki-tang and atezolizumab is a safe treatment option for non-small cell lung cancer. Clinical studies are warranted to confirm this finding. Frontiers Media S.A. 2023-05-18 /pmc/articles/PMC10232755/ /pubmed/37274110 http://dx.doi.org/10.3389/fphar.2023.1181263 Text en Copyright © 2023 Yang, Yi, Chun, Park, Bui, Yun, Chae and Jeong. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Yang, Sung-Yoon Yi, Jin-Mu Chun, Jaemoo Park, Seongwon Bui, Tham Thi Yun, Hwi-Yeol Chae, Jung-Woo Jeong, Mi-Kyung Evaluation of the potential herb-drug interaction between Bojungikki-tang and PD-L1 immunotherapy in a syngeneic mouse model |
title | Evaluation of the potential herb-drug interaction between Bojungikki-tang and PD-L1 immunotherapy in a syngeneic mouse model |
title_full | Evaluation of the potential herb-drug interaction between Bojungikki-tang and PD-L1 immunotherapy in a syngeneic mouse model |
title_fullStr | Evaluation of the potential herb-drug interaction between Bojungikki-tang and PD-L1 immunotherapy in a syngeneic mouse model |
title_full_unstemmed | Evaluation of the potential herb-drug interaction between Bojungikki-tang and PD-L1 immunotherapy in a syngeneic mouse model |
title_short | Evaluation of the potential herb-drug interaction between Bojungikki-tang and PD-L1 immunotherapy in a syngeneic mouse model |
title_sort | evaluation of the potential herb-drug interaction between bojungikki-tang and pd-l1 immunotherapy in a syngeneic mouse model |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232755/ https://www.ncbi.nlm.nih.gov/pubmed/37274110 http://dx.doi.org/10.3389/fphar.2023.1181263 |
work_keys_str_mv | AT yangsungyoon evaluationofthepotentialherbdruginteractionbetweenbojungikkitangandpdl1immunotherapyinasyngeneicmousemodel AT yijinmu evaluationofthepotentialherbdruginteractionbetweenbojungikkitangandpdl1immunotherapyinasyngeneicmousemodel AT chunjaemoo evaluationofthepotentialherbdruginteractionbetweenbojungikkitangandpdl1immunotherapyinasyngeneicmousemodel AT parkseongwon evaluationofthepotentialherbdruginteractionbetweenbojungikkitangandpdl1immunotherapyinasyngeneicmousemodel AT buithamthi evaluationofthepotentialherbdruginteractionbetweenbojungikkitangandpdl1immunotherapyinasyngeneicmousemodel AT yunhwiyeol evaluationofthepotentialherbdruginteractionbetweenbojungikkitangandpdl1immunotherapyinasyngeneicmousemodel AT chaejungwoo evaluationofthepotentialherbdruginteractionbetweenbojungikkitangandpdl1immunotherapyinasyngeneicmousemodel AT jeongmikyung evaluationofthepotentialherbdruginteractionbetweenbojungikkitangandpdl1immunotherapyinasyngeneicmousemodel |